What IV antibiotic should be used to treat an Enterococcus urinary tract infection?

IV Antibiotic for Enterococcus UTI

For vancomycin-susceptible Enterococcus UTI requiring IV therapy, use ampicillin 18-30 g IV daily in divided doses; for vancomycin-resistant Enterococcus (VRE) UTI, use linezolid 600 mg IV every 12 hours as first-line therapy. 1

Treatment Algorithm Based on Susceptibility

Vancomycin-Susceptible Enterococcus

• Ampicillin-susceptible strains: Ampicillin is the drug of choice for all enterococcal UTIs when susceptible, regardless of vancomycin resistance status 1
  • Dosing: 18-30 g IV daily in divided doses for complicated UTI
  • Alternative: Amoxicillin 500 mg IV every 8 hours 1
  • High urinary concentrations can overcome elevated MICs, making ampicillin effective even for some resistant strains in UTI specifically 1

Vancomycin-Resistant Enterococcus (VRE)

For uncomplicated VRE cystitis:

• Consider oral options first if patient can tolerate:
  • Fosfomycin 3 g PO single dose 1
  • Nitrofurantoin 100 mg PO every 6 hours 1
  • High-dose ampicillin if ampicillin-susceptible (even if VRE) 1

For complicated VRE UTI or pyelonephritis requiring IV therapy:

• First-line: Linezolid 600 mg IV every 12 hours (strong recommendation) 1

  • FDA-approved for VRE infections
  • Clinical cure rates: 86.4%, microbiological cure: 81.4% 1
  • Can transition to oral formulation when appropriate
  • Active against both E. faecium and E. faecalis

• Alternative: High-dose daptomycin 8-12 mg/kg IV daily (weak recommendation) 1

  • Reserved for bacteremic or severe VRE UTI
  • Critical caveat: Daptomycin achieves low serum levels and should NOT be used for simple cystitis 1
  • Consider combination with β-lactams (penicillins, cephalosporins, or carbapenems) for synergy in bacteremia 1
  • Mortality data shows conflicting results: some studies favor linezolid (32.8% vs 35.7%), others show no difference 1

Species-Specific Considerations

E. faecalis vs E. faecium:

• E. faecalis (77.3% of cases): Lower resistance rates, better outcomes, mortality 10.1% 2
• E. faecium (22.7% of cases): Higher antibiotic resistance, mortality 23%, longer hospital stays 2
• VRE E. faecium has <15% susceptibility to ampicillin, ciprofloxacin, nitrofurantoin, and tetracycline—linezolid remains >90% effective 3
• VRE E. faecalis retains >90% susceptibility to ampicillin, linezolid, and nitrofurantoin 3

Critical Pitfalls to Avoid

1. Do not use tigecycline for UTI: Despite activity against VRE, tigecycline has large volume of distribution and low serum/urinary levels—reserve only for intra-abdominal VRE infections 1

2. Differentiate colonization from infection: Unnecessary VRE treatment in colonized patients is a major problem 1, 4. Treat only with:

   • Urinary symptoms (dysuria, frequency, urgency)
   • Fever/systemic signs
   • Pyuria with ≥10⁵ CFU/mL 2

3. Remove urinary catheters when possible: Catheter-associated UTIs respond better after catheter exchange or removal before culture collection 5, 6

4. Check ampicillin susceptibility even in VRE: High urinary ampicillin concentrations may overcome resistance in UTI specifically, with clinical cure rates of 88.1% and microbiological eradication 86% for ampicillin-resistant VRE UTI 1

Duration of Therapy

Duration depends on infection severity and clinical response 1:

• Uncomplicated cystitis: 3-5 days (single dose for fosfomycin)
• Complicated UTI/pyelonephritis: 7-14 days based on clinical response
• Bacteremic UTI: Minimum 14 days

Risk Factors for VRE UTI

Patients at highest risk include those with 5, 2:

• Urinary catheterization (59.3% of cases)
• Recent antibiotic use within 3 months (51.8%)
• Hospitalization, especially non-ICU wards (66.4%)
• Prior healthcare exposure or known VRE colonization